Appln. No. 09/522,727 Amendment dated May 9, 2005 Response to Office Action dated February 7, 2005

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1. (WITHDRAWN) A method of inhibiting an undesired MHC class 1 immune associated reaction comprising transducing a cell that can be involved in the undesired MHC class 1 immune associated reaction with a first gene encoding an antibody, wherein said antibody when expressed will bind in the cell to a target molecule involved in the undesired MHC class 1 immune associated reaction, expressing the antibody and letting said antibody bind to said target molecule, and also transducing said cell with a second gene encoding an MHC-1 analog that is deficient in its ability to initiate an MHC class 1 reaction, wherein said MHC-1 analog will not initiate the NK (Natural Killer) reaction.
 - 2. (CANCEL)
 - 3. (CANCEL)
- 4. (WITHDRAWN) The method of claim 1, wherein the antibody comprises a single chain antibody.
 - 5. (CANCEL)
 - 6. (CANCEL)
- 7. (WITHDRAWN) The method of claim 1, wherein said antibody binds to an MHC Class I component selected from the group consisting of MHC Class I α chains, β2 microglobulin, calnexin, transporter associated with antigen processing (TAP) and tapasin.

Appln. No. 09/522,727 Amendment dated May 9, 2005 Response to Office Action dated February 7, 2005

- 8. (WITHDRAWN) A cell transduced by a gene encoding an antibody that binds to a target molecule, wherein said target molecule is a component of the major histocompatibility complex (MHC), having said antibody expressed, wherein said expressed antibody binds to the target molecule in the cell and inhibits said cell from being part of an undesired immune associated reaction.
- 9. (WITHDRAWN) The cell of claim 8, wherein said antibody binds to one of the group of MHC components selected from X chains of the MHC, β2 microglobulin, calnexin, transporter associated with antigen processing (TAP) and tapasin.
 - 10. (WITHDRAWN) The cell of claim 9, wherein said antibody binds to TAP.
- 11. (WITHDRAWN) The cell of claim 9, wherein the antibody is a single chain antibody.
- 12. (WITHDRAWN) A kit containing a vector containing a gene that encodes an antibody that binds to a component of the major histocompatibility complex (MHC), wherein said antibody has been adapted to remain in the cell, and instructions for its use in inhibiting undesired immune associated reactions.
- 13. (WITHDRAWN) The method of claim 1, wherein the target molecule is an MHC class I molecule, and the undesired immune reaction is tissue rejection during transplantation.
- 14. (WITHDRAWN) The method of claim 1, wherein the target molecule is an MHC class I molecule, and the undesired immune reaction is an autoimmune disease.
- 15. (WITHDRAWN) The method of claim 1, wherein the target molecule is an MHC class I molecule, and the undesired immune reaction is tissue rejection during bone marrow transplantation.

Appln. No. 09/522,727 Amendment dated May 9, 2005 Response to Office Action dated February 7, 2005

- 16. (WITHDRAWN) The method of claim 13, wherein the cell is an antigen presenting cell.
 - 17. (WITHDRAWN) The method of claim 13, wherein the cell is a B cell.
- 18. (PREVIOUSLY PRESENTED) A method of inhibiting a specific undesired immune associated reaction, comprising transducing a cell that can be involved in the undesired immune associated reaction with a gene encoding an antibody, wherein said antibody when expressed will bind in the cell to a target molecule involved in the undesired immune associated reaction, expressing the antibody and letting said antibody bind to said target molecule, wherein the gene encoding the antibody is comprised of a gene encoding a heavy chain of the antibody linked by an internal ribosome entry site (IRES) to a gene encoding a light chain of the antibody.
- 19. (PREVIOUSLY PRESENTED) The method of claim 18, wherein the antibody is a Fab.
- 20. (WITHDRAWN) The method of claim 1, wherein the gene encoding the antibody is in an RNA or DNA vector.
- 21. (WITHDRAWN) The method of claim 20, wherein the gene encoding the antibody is in a DNA vector.
- 22. (PREVIOUSLY PRESENTED) The method of claim 18, wherein the gene encoding the antibody is in a retroviral vector.
- 23. (PREVIOUSLY PRESENTED) The method of claim 22, wherein the retroviral vector is a lentivirus vector.
 - 24. (WITHDRAWN) The method of claim 1, wherein the MHC-1 analog is an MHC-1 molecule that lacks its cytoplasmic domain.